EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Systemic Inflammation Indices and Association with Prostate Cancer Survival in a Diverse Patient Cohort

Maeve Bailey-Whyte iD, Tsion Z Minas, Tiffany H Dorsey, Cheryl J Smith, Christopher A Loffredo, Stefan Ambs iD

Cancers · 20.03.2023 · 15 (6) · 1869

DOI: 10.3390/cancers15061869 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 20.03.2023. Verfasst von Maeve Bailey-Whyte und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Limerick, V94 XD21 Limerick, Ireland. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United States Department of Defense, NIH HHS, Health Research Board.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is a lack of investigations assessing the performance of systemic inflammation indices as outcome predictive tools in African Americans with prostate cancer. This study aims to assess the relationships between neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation (SII), and systemic inflammation response index (SIRI) with survival outcomes among 680 diverse men with prostate cancer. Routine blood results were collected from self-identified African American and European American patients. We applied multivariable Cox regression modeling to examine the associations of systemic inflammation indices with overall and prostate cancer-specific survival. The median survival follow-up was 5.9 years, with 194 deaths. NLR, SII, and SIRI, but not PLR, showed associations with all-cause and prostate cancer-specific mortality when coded as dichotomized and continuous variables. NLR and SIRI were significantly associated with prostate cancer-specific mortality among all men (hazard ratio (HR) 2.56 for high vs. low NLR; HR 3.24 for high vs. low SIRI) and African American men (HR 2.96 for high vs. low NLR; HR 3.19 for high vs. low SIRI). Among European Americans, only SII showed an association with prostate cancer-specific survival. These observations suggest that inflammation indices merit further study as predictors of prostate cancer mortality.

Schlagwörter

Stichwörter der Autor:innen

African Americanhealth disparityinflammationprostate cancersystemic inflammation indices

Autor:innen und Institutionen

  • School of Medicine, University of Limerick, V94 XD21 Limerick, Ireland.
  • Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
  • Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA.

ORCID-Profile: Maeve Bailey-Whyte, Stefan Ambs

Förderung

  • United States Department of Defense
  • NIH HHS
  • Health Research Board
  • Intramural Research Program of the NIH
  • National Cancer Institute (NCI)
  • Center for Cancer Research
  • DoD
  • NCI Cancer Prevention Fellowship program

Zitieren

APA

Bailey-Whyte, M., Minas, T. Z., Dorsey, T. H., Smith, C. J., Loffredo, C. A., & Ambs, S. (2023). Systemic Inflammation Indices and Association with Prostate Cancer Survival in a Diverse Patient Cohort. Cancers, 15(6), 1869. https://doi.org/10.3390/cancers15061869

Vancouver

Bailey-Whyte M, Minas TZ, Dorsey TH, Smith CJ, Loffredo CA, Ambs S. Systemic Inflammation Indices and Association with Prostate Cancer Survival in a Diverse Patient Cohort. Cancers. 2023;15(6):1869. doi:10.3390/cancers15061869

BibTeX
@article{BaileyWhyte2023,
  author = {Bailey-Whyte, Maeve and Minas, Tsion Z and Dorsey, Tiffany H and Smith, Cheryl J and Loffredo, Christopher A and Ambs, Stefan},
  title = {Systemic Inflammation Indices and Association with Prostate Cancer Survival in a Diverse Patient Cohort},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {6},
  pages = {1869},
  doi = {10.3390/cancers15061869}
}
Kostenlos starten →